Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | STK16 | O75716 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.44 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | ULK1 | O75385 | 2/20 | 0.44 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.44 |
| ▸ | MARK3 | P27448 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284997 | 0.94 | TBK1 (0.47) | TBK1JAK3CDK1KDREGFR | |
| SCHEMBL1285268 | 0.93 | AURKA (0.46) | TBK1JAK3CDK1KDREGFR | |
| SCHEMBL27844363 | 0.92 | TBK1 (0.55) | TBK1JAK3CDK1KDREGFR | |
| SCHEMBL1284577 | 0.88 | HDAC3 (0.47) | TBK1JAK3EGFRCDK2CCNA2 | |
| SCHEMBL27844447 | 0.85 | AURKA (0.47) | TBK1JAK3CDK1KDREGFR | |
| SCHEMBL1284543 | 0.84 | STAT6 (0.51) | CDK1CSF1RCDK2AURKACCNA2 | |
| SCHEMBL1285558 | 0.84 | CDK4 (0.45) | TBK1JAK3CDK1KDREGFR | |
| SCHEMBL1284834 | 0.84 | JAK3 (0.47) | TBK1JAK3KDRTYK2JAK2 | |
| SCHEMBL1284750 | 0.83 | MAP3K5 (0.46) | JAK3EGFRAURKACDK4JAK2 | |
| SCHEMBL1285070 | 0.82 | CDK4 (0.45) | TBK1JAK3CDK1KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885JAK3 20/4885CDK1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.